Sanguine Biosciences Using VERIF.i® on Scientist.com

Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that Sanguine Biosciences, a leading biospecimen provider that connects researchers to the biospecimens they need with a direct-to-donor model to accelerate precision medicine and cell and gene therapy research and development, has successfully completed a VERIF.i® on-site assessment. VERIF.i helps Scientist.com marketplace suppliers demonstrate internal processes and adherence to best practices to both existing and potential new clients.

“Through direct-to-donor engagement, Sanguine continues to amass one of the industry’s largest collections of ethically procured collections that includes extensive data about the biospecimens,” stated Sanguine CEO Brian Neman. “Scientist.com’s VERIF.i program enables us to further demonstrate the exceptional quality of our biospecimen and biorepository services and the commitment of our team to bridge the gap between donors and researchers.”

Sanguine supports translational, clinical, and cell and gene therapy research, and their services include prospective in-home biospecimen collection directly from their donor network, apheresis products including leukopaks and LeukoLots™, biospecimen inventory, and biorepository services. Their research products and services facilitate advanced therapy development programs from discovery to manufacturing.

“Human biological samples increasingly represent critical tools in the drug discovery and development process, but researchers in the life sciences often have difficulty finding high-quality, ethically sourced human samples,” stated Matt McLoughlin, SVP of Categories & Compliance at Scientist.com. “VERIF.i was developed to create a standardized process that helps researchers and sample providers ensure that the samples used in research meet their expected quality and ethical standards.”